Connect with us

Healthcare

Premier Health (PHGI) (PHGRF) Signs Partnership Agreement with Navigator Genomics to Provide Pharmacogenomic Testing & Medical Cannabis Educational Content to Patients

Joe Samuel

Published

on

stock_price_weed

VANCOUVER, British Columbia, May 29, 2019 (GLOBE NEWSWIRE) — Premier Health Group (CSE: PHGI, OTCQB: PHGRF, Frankfurt: 6PH) (the “Company” or “Premier Health”), a Company focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry, is pleased to announce it is working with Navigator Genomics (NGT) to provide access to their first-of-its kind Pharmacogenomic Testing for medical cannabis and 416 of the most popularly prescribed medications.

According to a study by Scipher Medicine, 65% of patients prescribed the world’s top five selling drugs didn’t respond to the therapy. NGT’s simple saliva swab testing provides patients, and their healthcare team with the patient’s genetic metabolism and ability to effectively utilize both medical cannabis and prescription drugs. The comprehensive, but easy to read, report also includes potential drug to drug interactions, inhibitors and inducers. The tests are sold direct-to-consumer, or to their doctor, and patients will have the option to share the results with their healthcare team which can then be integrated directly into Premier Health’s Juno EMR software and MyHealthAccess app. Through the telemedicine feature on the app, patients can directly discuss their results with their doctor.

NGT will also provide educational material such as news articles, links to fully vetted cannabis glossaries, videos, webinars, science whitepapers, & chronic medical condition information focused on the very same conditions consumers must have to qualify for medical cannabis directly on Premier Health’s app.

“Personalized medicine, also known as pharmacogenomics, is increasingly impacting drug research and health care technology,” said Dr. Essam Hamza, CEO of Premier Health. “The genetic make up from patient to patient can vary significantly which can greatly impact the efficacy of different medications including medical cannabis. This individualized approach to medicine allows for a much more tailored and personalized treatment plan. Through our patient centric app, we are aiming to provide the most robust and advanced health technology and medical information right at the patient’s fingertips. By offering to place NGT test results directly into our Juno EMR and app, we can ensure our patients are prescribed the best medication and avoid those that simply do not genetically work or are possibly harmful. We look forward to expanding our partnership further with NGT over time.”

NGT has agreed to offer a 10% discount on its genetic testing kit to PHG patients and doctors using the following link: https: // navigatorgenomics .com /phg10/.

Navigator Genomics™ Testing; Travis Parr – Founder & CEO states, “Medical Cannabis is used by people who have specific chronic medical conditions who wish to reduce their symptoms and the number or doses of prescription drugs they may be taking. Navigator Genomics tests use a simple saliva cheek swab done at home, & our proprietary machine-learning tools provide Actionable Information, reporting each person’s unique genetic responses for the key cannabinoids found in medical cannabis simultaneously with 416 of the most popularly prescribed medications. Besides the recommendations of what drugs and cannabinoids can work best for you, NGT reports on your potential MMJ-Drug-to-Drug interactions. Such interactions can lessen the effectiveness of your medical cannabis, or your prescription drugs and often can cause unwanted side effects. Your results can lead you to receiving ‘personalized medicine’ from your doctors and dispensaries who can then prescribe what will work best and the medications for you to avoid. Consumers can thus avoid ‘trial and error’ while saving significant time and money and improve their overall quality of life.

“Premier’s Juno EMR and app should significantly improve clinical treatments for each patient where medical cannabis and prescription drugs are an active part of treatment.”

ON BEHALF OF THE BOARD OF DIRECTORS
“Dr. Essam Hamza, MD”
Chief Executive Officer

About Premier Health

Premier Health is a Canadian company that is strategically poised to take advantage of business opportunities in the global health care industry. We are focused on innovative health care approaches that combine human skill-based expertise with emerging technologies. Premier Health, in conjunction with its subsidiary Cloud Practice, a cloud-based SAAS Electronic Medical Records software company, is developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence (AI). We currently have a combined ecosystem of 290 clinics, over 3,000 licensed practitioners and almost 3 million registered patients. The Premier Health team has deep clinical, operational and financial expertise and a passion for improving healthcare for all patients.

For more information on Premier Health, please visit www. mypremierhealth .com.
For more information on Juno EMR, please visit www. junoemr .com.

About Navigator Genomics

NGT is the first evidence-based pharmacogenomics company to measure & report personalized genetic responses to key cannabinoids utilized in Medical Cannabis (MMJ), simultaneously with 416 of the most popularly prescribed prescription medications (Rx) taken by the most amount of people. Results include important potential drug-drug interactions which can reduce or cancel efficacy of MMJ or Rx’s, create unwanted side-effects or even adverse reactions. Consumers can avoid costs & time of traditional “trial and error” dosing. Results help personalize which cannabinoids & medications can work best for each person.

For more information about NGT, please visit https:// navigatorgenomics .com.
For a 10% discount on your personalized genetic testing kit, please visit https:// navigatorgenomics .com /phg10/.

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release.

FOR ADDITIONAL INFORMATION CONTACT:

Premier Health Group Inc.
www. mypremierhealth .com
Email: investors@ mypremierhealth .com

Renmark Financial Communications Inc.
Bettina Filippone: bfilippone @ renmarkfinancial .com
Tel:(416) 644-2020 or (514) 939-3989
www. renmarkfinancial .com

Continue Reading
Click to comment

Featured

3 Biotechnology Stocks To Know Before 2020

Daniel Chase

Published

on

healthcare stocks to buy now

Over the course of the past half a decade or so, biotech stocks have managed to emerge as an excellent investment option for thousands of investors. If the words of market experts are to be believed then the sector is going to continue to throw up gems for the foreseeable future.

However, if one is to make the right picks then research ais key. One of the best ways of going about it is to make a list of some of the top biotech stocks to watch. Looking for news, corporate filings and other pivotal updates from companies is one place to start. After several key developments, here is a look at three biotechnology companies to take a closer look at before next year.

GT Biopharma Inc. (GTBP)

This company’s stock made new 3 month highs on October 22. GT Biopharma (GTBP) announced that its solid tumor targeting TriKE killed a non-small cell lung cancer tumor cell. This is a major development news for the company’s TriKE platform because the market potential for non-small lung cancer is big.

[BREAKING NEWS] GT Biopharma (GTBP) Announces Solid Tumor Targeting TriKe™ Kills Non-small Cell Lung Cancer (NSCLC) Tumor Cells

Non-small lung cancer accounts for 84% of all lung cancer diagnoses. Shareholders clearly felt this way, which may have been why GT Biopharma’s stock shot up by more than 25%.

penny stocks to watch Aclaris Therapeutics (ACRS)

There could be another potential reason why stockholders are reacting this way to the recent news. Earlier in October, the company announced that the design of HIV-TriKE was able to successfully target the HIV-Env protein.

This would allow the company’s TriKE technology to eliminate replicating HIV infected cells. Because of the success of TriKE with lung cancer cells, investors might feel that the company will be able to successfully destroy HIV cells. For more on GT Biopharma’s novel treatment pipeline and progress, click here.

WHAT CURING CANCER & HIV COULD MEAN FOR THIS COMPANY, ITS INVESTORS & THE WORLD!

Kadmon Holdings (KDMN)

The first biotech stock to put into the watch list is that of Kadmon Holdings Inc (NYSE:KDMN), which made a major announcement yesterday. The company’s lead product KD025, which is meant for the treatment of chronic graft-vs-host disease has managed to meet the primary endpoint. The findings were revealed from an interim analysis of the medicine.

Enrolment for the same had taken place around two months ago and it goes without saying that it is a significant development for the company. Patients who were administered 200 mg doses recorded an objective response rate of 64%, while those who had been administered 250 mg ones recorded 67% in the same metric.

The stock rose by as much as 23.40% in Tuesday’s trading and made a new 52-week high of 3.74. The stock has gained over 63% so far in 2019.

WHAT CURING CANCER & HIV COULD MEAN FOR THIS COMPANY, ITS INVESTORS & THE WORLD!

Arcadia Biosciences (RKDA)

The other biotech stock that experienced an impressive rally is that of Arcadia Biosciences Inc (NASDAQ:RKDA). On November 12, Verdeca, a joint venture formed by Arcadia and Bioceres Crop Solutions Corp, made a significant announcement with regards to one of its products.

Verdeca announced that the National Commission for Agricultural and Forestry Biosafety, which is under the control of the Paraguayan Minister of Agriculture, has approved its HB4 soya beans.

The particular variant of soya beans can tolerate both herbicide and drought. The approval resulted in a rally in the Arcadia stock and it climbed by as much as 7%.

best biotech stocks to watch today

Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.

Continue Reading

Biotechnology

These Biotech Stocks Have Grabbed Attention On Latest Sector Move

Joe Samuel

Published

on

Biotech stocks have been on a good run over the past few weeks. Considering the sort of work that most companies have done over the past few years, novel treatments have been discovered. So, it’s quite clear that there may still be plenty of opportunities waiting to be grabbed by investors

In order to do it some degree of success; one would need to watch the market closely. Many biotech stocks have made moves over the past weeks and here is a look at two of them that should be watched closely by investors.

Biotech Stocks To Watch: Sernova (SVA) (SEOVF) Garners Interest From Analysts

Echelon Wealth Partners analyst Douglas Loe thinks Sernova (TSX:SVA) (OTC:SEOVF) has massive upside [SOURCE]. Not only did the analyst give a $1 price target for the stock he also backed up his “Speculative Buy” rating with a clear explanation of the company’s future prospects.

Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial to assess the safety and tolerability of islet transplantation into the company’s patented Cell Pouch in participants with diabetes and hypoglycemia unawareness. 

Why This Could Be Important to Understand

The detection of fasting C-peptide in the bloodstream of its first patient, in addition to Sernova’s recent announcement of glucose-stimulated C-peptide and other early efficacy indicators, demonstrate a normalizing response of the Cell Pouch therapeutic cells to the body’s need for insulin production. This is an important step forward and “evidence of ongoing islet engraftment within the Cell Pouch,” according to the company.

[See How The Sernova Cell Pouch Could Change Drug Delivery Forever]

Biotech Stocks To Watch: Navidea Biopharmaceuticals (NAVB) Jumps On NAV3-31’s Data

The first one to consider in this regard is the Navidea Biopharmaceuticals Inc (NYSE:NAVB) stock, which has been on a tear this morning following a major announcement. This month, the company released highly positive interim data from the Phase 2B clinical study of its product NAV3-31. The product in question is meant for the treatment of active rheumatoid arthritis and the data revealed that it is effective.

As soon as the development hit the news wires, the Navidea stock soared significantly. In early morning trade, the stock rose by as much as 40% to emerge as one of the biggest gainers. It goes without saying that this is a track that should be tracked closely by investors over the coming days.

Biotech Stocks To Watch: Lexicon Pharmaceuticals (LXRX) Soars 190% in 2-Month

The other biotech stock that has been in the middle of a sustained rally for close to two months is that of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX). Back in September, the company canceled a partnership with Sanofi by way of which it was going to produce the diabetic medicine Zynquista.

Due to the termination, the company is going to be paid a total of $260 million and the rights of the product in question are going to pass on to Lexicon as well. Since then the stock has been in an impressive run. In September alone, it rose by as much as 190% and it has carried on the momentum into October. It has gained 35% in October so far.

biotech stocks to buy

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and Sernova (TSX:SVA) (OTC:SEOVF), Midam has been paid $350,000 for a period from September 23, 2019 to September 22, 2020. We may buy or sell additional shares of Sernova (TSX:SVA) (OTC:SEOVF) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about Sernova (TSX:SVA) (OTC:SEOVF). Click Here For Full Disclaimer.

Continue Reading

Biotechnology

Biotech ETF’s Just Hit New Highs: 3 Stocks To Watch

Joe Samuel

Published

on

biotech penny stocks to buy

Biotech & Healthcare ETF’s Made New October Highs; Watching Sector Stocks?

There are certain sectors in the stock market that regularly excite investors. Much of that has to do with the core strength of the sector in question. While tech has been such a sector for more than three decades now, the biotech sector has also been a sector that has helped investors make excellent returns for many years now.

Over the last few trading sessions, both the IBB and XLV ETF’s have taken off to make new October highs. So why wouldn’t healthcare and biotechnology catch someone’s eye?

The biotech sector has a plethora of stocks though. Therefore, an investor needs to put in the necessary research. On that note, here is a look at three biotech stocks to watch as sector stocks enjoy a bull run in October.

GT Biopharma (GTBP) Pops After HIV Data Presentation

GT Biopharma, Inc. (GTBP) is an immuno-oncology company focused on innovative treatments based on the Company’s patent-pending TriKE™ technology. It’s also a biotech stock that has been on the move this month. Earlier in October the company announced key presentation data on its HIV TriKE™ platform.

GT Biopharma (GTBP) Announces HIV TriKE™ Data Demonstrating NK Cell Killing of Patient HIV Infected Cells

Tim Schacker , M.D., Jeffrey S. Miller , M.D., and their colleagues at the University of Minnesota presented data during a poster session held at the 18th meeting of the Society for Natural Immunity in Luxembourg.

biotechnology stocks to watch

Research findings from Dr. Schacker’s and Dr. Miller’s laboratories show enhanced NK cell cytokine production and killing of infected targets expressing HIV-Env when incubated with the HIV-TriKE™. This could be a big step for the company and one that has caught some attention this month.

In comparison, the use of anti-retroviral drugs have substantially improved the health and increased the longevity of individuals infected with the human immunodeficiency virus (HIV). But these drugs are designed to suppress virus replication to help modulate progression to AIDS and to limit further transmission of the virus. In this case, GTBP’s HIV-TriKE™ was actually able to kill HIV in the reservoir.

Achillion Pharmaceuticals (ACHN) Jumps On Buyout

One of the biotech stocks that made a remarkable move this week was Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) after it was announced that the company was going to be acquired by Alexion Pharmaceuticals. According to the announcement, Achillion is going to be acquired in a deal worth $930 million.

 It is a deal that is going to be completed entirely in cash. Alexion is paying a premium of 73% above the closing price of the Achillion stock on Tuesday. That works out to a price of $6.30 a share and on Tuesday, the stock had closed at $3.65 a share.

The announcement lit a fire on the Achillion stock and it zoomed by as much as 75% on Wednesday. Considering the sort of premium that is being paid, it is not really a surprise for most market watchers to take notice.

Atossa Genetics (ATOS) Gains On Phase 2 clinical study

The other biotech stock that is in the news today is that of Atossa Genetics Inc (NASDAQ:ATOS). The clinical-stage biopharmaceutical company that is engaged in developing treatments for breast cancer, made a major announcement.

[REPORT] BIOTECH INVESTORS TURN ATTENTION TO TARGETED TREATMENT; ONE COMPANY STANDS OUT

It has been announced that its microcatheter technology has been approved for a Phase 2 clinical study by the Institutional Review Board (IRB).

The technology helps in administering fulvestrant in breast cancer patients and could have major implications for the company’s long term growth. The market believed so as well and the Atossa stock climbed as much as 4.50% after the news broke on Wednesday.

biotechnology stocks to buy now

Disclaimer: Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), Midam has been paid $100,000 for a period from October 1, 2019 to November 15, 2019. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.

Continue Reading

Join Our Newsletter

Get stock alerts, news & trending stock alerts straight to your inbox!


Privacy Policy

We keep all user information pricate & promise to never spam.*

Stock Price Free Text List

Search Stock Price (StockPrice.com)




Trending

Subscribe Now & Begin Receiving Free Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Stock Market & Finance, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on stock market & finance related, articles, news and trade alerts. Further questions please contact privacy@stockprice.com